Funding has been preferred for higher-profile cancers, such as breast and prostate
More than half the women who are diagnosed with ovarian cancer die within 5 years. That makes ovarian cancer the most deadly gynecologic cancer. What's worse is that the survival rate hasn't gotten any better over the past 50 years, despite how quickly technology and modern medicine has progressed in that period of time. Why? Because of the severe underfunding of ovarian cancer research. The Canadian Institutes of Health Research is a government organization that is in charge of allocating funding for health research. Unfortunately for ovarian cancer, funds have always been much less than other cancers. That's because they prioritize funding for higher profile cancers with higher incidence and mortality - such as breast and prostate cancer.